Role of selective progesterone receptor modulators in the treatment of symptomatic uterine fibroids

Neha Naresh, Poonam Mani, Lalita Yadav, Nidhi Singh


Background: Uterine leiomyomas are benign tumours of smooth muscle cells and fibrous tissue that develop within the wall of the uterus. Objective of this study was to compare efficacy and safety of Mifepristone and Ulipristal acetate in the treatment of symptomatic uterine fibroids.

Methods: The present randomized comparative prospective study was conducted among 120 non-pregnant and non-lactating females of age 25-50 years with symptomatic fibroids reported in the department of obstetrics and gynecology, Chhatrapati Shivaji Subharti Hospital, Meerut, Uttar Pradesh for a duration of 2 years from September 2017 to July 2019.The selected subjects were divided into two treatment arms i.e. Group 1: ulipristal acetate: 5 mg OD for 3 months and Group 2: mifepristone: 25 mg OD for 3 months. Detailed history of the patient, general physical examination and systemic examination was done followed by per abdomen examination, per speculum and per vaginal examination. A blood examination, USG (pelvis), Pap smear and endometrial biopsy was done. Subjects visited the hospital at visit 1, visit 2, visit 3, visit 4, visit 5 and visit 6 for 6 months.

Results: In both the groups, maximum subjects were in the age group of 36-40 years, followed by 41-50 years. When mean PBAC score at first, second, third, fourth and fifth visit was compared statistically among ulipristal acetate and mifepristone group, it was found to be statistically significant. Uterine pain was reduced more in mifepristone group as compared to ulipristal acetate group at all the different intervals. Size was reduced more in mifepristone group as compared to ulipristal acetate group at all the different intervals.

Conclusions: Authors conclude from this study that mifepristone should be preferred over ulipristal acetate for treatment of symptomatic fibroids.


Fibroid uterus, Heavy menstrual bleeding, Mifepristone, Ulipristal acetate

Full Text:



Munro MG, Critchley HO, Broder MS, Fraser IS. FIGO Working group on menstrual disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113(1):3-13.

Lumsden MA, Wallace EM. Clinical presentation of uterine fibroids. Baillieres Clin Obstet Gynaecol. 1998;12:177-95.

Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol. 1990;94(4):435-8.

Marshall LM, Spiegelman D, Barbieri RL. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997;90(6):967-73.

Vollenhoven B. Introduction: the epidemiology of uterine leiomyomas. Baillieres Clin Obstet Gynaecol. 1998;12(2):169-76.

Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100-7.

Olive DL, Pritts EA. Fibroids and reproduction. Semin Reprod Med. 2010;28(3):218-27.

Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Human Reprod Update. 2016;22(6):665-86.

Williams AR. Uterine fibroids-what’s new? F1000Res. 2017;6.

Khan AT, Shehmar M, Gupta JK. Uterine fibroids: current perspectives. Int J Women's Health. 2014;6:95.

Han NL, Ong CL. Magnetic resonance-guided focused ultrasound surgery (MRgFUS) of uterine fibroids in Singapore. Ann Acad Med Singapore. 2014;43(11):550-8.

Song H, Lu D, Navaratnam K, Shi G. Aromatase inhibitors for uterine fibroids. Cochrane Database Syst Rev. 2013;10:CD009505.

Wiehle R. Effects of a new progesterone receptor modulator, CDB-4124, on fibroid size and uterine bleeding. US Obstet Gynecol. 2008;3(1):17-20.

Engman M, Granberg S, Williams AR. Mifepristone for treatment of uterineleiomyoma. A prospective randomized placebo-controlled trial. Hum Reprod. 2009;24(8):1870-9.

Bestel E, Donnez J. The potential of selective progesterone receptor modulators for the treatment of uterine fibroids. Expert Rev Endocrinol Metab. 2014;9(1):79-92.

Wozniak S, Szkodziak P, Czuczwar P. The effect of ulipristal acetate treatment on symptomatic uterine fibroids within 12-months follow-up. Przegla d Menopauzalny Menopause Rev. 2014;13(1):18-21.

Arora D, Chawla J, Kochar SP, Sharma JC. A randomized control trial to assess efficacy of Mifepristone in medical management of uterine fibroid. Med J Arm Forces India. 2017;73(3):267-73.

Shradha AK, Sahay PB. Role of Mifepristone in medical management of uterine fibroid. J Obst Gyn India. 2002;52(5):52-3.

Kale AR. Comparison between mifepristone and ulipristal acetate as an alternative to surgical management of uterine fibroids (leiomyoma) in symptomatic patients of reproductive age group in Asian population. Int J Reprod Contracept Obstet Gynecol. 2018;7:109-13.

Seth S, Goel N, Singh E, Mathur AS, Gupta G. Effect of mifepristone (25 mg) in treatment of uterine myoma in perimenopausal woman. J Mid-life Health. 2013;4:22-6.

Feng C, Meldrum S, Fiscella K. Improved quality of life is partly explained by fewer symptoms after treatment of fibroids with mifepristone. Int J Gynaecol Obstet. 2010;109(2):121-4.